cagrilintide novo nordisk with semaglutide has officially filed for FDA approval of CagriSema, a powerful new once-weekly injection that combines a GLP-1 receptor agonist an amylin analogue, setting the stage for the next major Novo Nordisk to explore CagriSema
Description
Dec;10:2866

Metabolic dysfunctionassociated steatohepatitis (MASH, formerly nonalcoholic steatohepatitis, NASH) is a major research focus, characterized by excessive hepatic fat accumulation, inflammation, and hepatocellular injury

No medication is one-size-fits-all

Ozawa J, Kaneguchi A, Minamimoto K, Tanaka R, Kito N, Moriyama H

Approval for this work was obtained from Biomodels LLC Institutional Animal Care and Use Committee (protocol number 17-0613-4)
